Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) had its price target raised by investment analysts at Morgan Stanley from $130.00 to $133.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley‘s target price suggests a potential upside of 79.88% from the stock’s current price.
A number of other equities research analysts have also recently commented on MNPR. Barclays reaffirmed an “overweight” rating and issued a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. HC Wainwright reissued a “buy” rating on shares of Monopar Therapeutics in a research report on Thursday. UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Zacks Research lowered Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $123.12.
Read Our Latest Research Report on MNPR
Monopar Therapeutics Stock Performance
MNPR stock traded up $1.94 during mid-day trading on Monday, hitting $73.94. The company had a trading volume of 30,128 shares, compared to its average volume of 202,448. The firm has a market cap of $496.29 million, a PE ratio of -30.65 and a beta of 1.62. Monopar Therapeutics has a 12 month low of $50.07 and a 12 month high of $124.82. The stock’s fifty day moving average price is $82.59 and its two-hundred day moving average price is $77.41.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.72) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.72). Equities analysts anticipate that Monopar Therapeutics will post -2.96 earnings per share for the current year.
Insider Buying and Selling at Monopar Therapeutics
In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $68.35, for a total transaction of $214,755.70. Following the sale, the director owned 5,373 shares of the company’s stock, valued at $367,244.55. The trade was a 36.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the business’s stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the sale, the chief executive officer directly owned 99,267 shares in the company, valued at $8,735,496. The trade was a 22.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 51,920 shares of company stock valued at $4,527,913. 9.70% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Monopar Therapeutics
Several hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new stake in Monopar Therapeutics during the 2nd quarter worth about $7,124,000. Siren L.L.C. boosted its stake in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares during the period. Bank of America Corp DE grew its holdings in Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after buying an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $3,458,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.
Further Reading
- Five stocks we like better than Monopar Therapeutics
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
